The Top Five Pharma Stories Of 2022
Scrip has taken a look back at five of the biggest story themes in no particular order of 2022 where once again the biopharma industry had plenty on its plate.
You may also be interested in...
Drug makers are more enthusiastic than ever about the outlook for developing drugs for Alzheimer's. Scrip reports back on the latest developments at CTAD.
Phase IIb KEYNOTE-942 study shows mRNA-4157/V940 paired with Keytruda reduces risk of recurrence and death in post-surgical melanoma patients compared with Keytruda alone.
Pfizer's strategy for building a mega-blockbuster brand around Nurtec ODT involves establishing oral CGRPs as first-line treatment.